ArunA Biomedical, Inc.

18 articles with ArunA Biomedical, Inc.

• ArunA Bio to Provide Corporate Update and Participate on a Panel at the 2019 BIO International Convention

  5/22/2019

  Panel Discussion Will Highlight Impact of Exosomes as Therapeutics and Drug Delivery Vehicles 

• ArunA Bio Appoints Al Medwar as Executive Vice President, Corporate and Commercial Development

  3/18/2019

  ArunA Bio, a leader in the development of exosomes and exosome therapeutics for the treatment of neurodegenerative disorders, announced the appointment of Al Medwar as Executive Vice President, Corporate and Commercial Development.

• ArunA Bio Appoints Dr. Mark Sirgo as Chief Executive Officer

  1/15/2019

  Dr. Steven Stice to Continue Leading Company’s Research and Manufacturing Operations

• ArunA Biomedical to Present and Participate on a Panel at 2018 BIO International Convention

  5/24/2018

  ArunA Biomedical today announced that Steven Stice, Ph.D., co-founder, chief executive and chief scientific officer, will present a corporate update and participate on a panel at the 2018 BIO International Convention occurring June 4-7, 2018 in Boston, MA.

• ArunA Biomedical Announces Oral Presentation of Preclinical Data at ISEV 2018

  4/25/2018

  ArunA Biomedical announced it will present data at the 2018 International Society for Extracellular Vesicles (ISEV) Annual Meeting occurring May 2-6 in Barcelona, Spain.

• ArunA Biomedical Announces Publication of Study in Stroke that Reports Exosomes Improved Tissue and Functional Recovery in Pig Model of Ischemic Stroke

  4/12/2018

  First company to demonstrate proof-of-concept of the therapeutic potential of extracellular vesicles in two divergent animal species and two stroke types

• ArunA Biomedical Launches New Class of Exosome Biologics to Treat Central Nervous System and Neurodegenerative Disorders

  1/3/2018

  With an initial focus on an exosome therapeutic for stroke, the company published results of a study today in Translational Stroke Research that found extracellular vesicles (EVs) derived from human neural stem cells improved tissue and functional recovery in murine thromboembolic stroke models.

• CryoPort, Inc. Supports Aruna Biomedical, Inc.'s Cryogenic Shipments Of Stem Cell Kits

  6/3/2015

• Aruna Biomedical, Inc. Announces Product Manufacturing and Distribution Agreement With Life Technologies

  9/24/2009

• Aruna Biomedical, Inc. Engages RiversEdge BioVentures to Evaluate Strategic Alternatives

  9/18/2009

• Aruna Biomedical, Inc. Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security

  3/31/2009

• Aruna Biomedical, Inc. Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells

  3/27/2009

• Aruna Biomedical, Inc. Announces Alliance with Neuromics, Inc. for Distribution of Normal Human Neural Cells

  3/24/2009

• Aruna Biomedical, Inc. Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells

  1/30/2009

• Aruna Biomedical, Inc.| Names Harold Ingalls to its Board of Directors

  9/10/2008

• Aruna Biomedical, Inc. Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells

  8/19/2008

• Aruna Biomedical, Inc. Names William T. Sharp President and Chief Executive Officer

  7/29/2008

• Aruna Biomedical, Inc. Announces Technology Licensing Agreement To Commercialize The First Products Derived From Human Embryonic Stem Cells

  1/25/2007